Pulmonary hypertension (PH) is a complex and progressive disease characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, often leading to right heart failure. This article aims to provide a comprehensive overview of PH, its pathophysiology, diagnosis, and treatment options.
PH is primarily a disease of the small pulmonary arteries, characterized by vascular remodeling, vasoconstriction, and in situ thrombosis. These changes lead to increased pulmonary vascular resistance, resulting in elevated pulmonary arterial pressure. Over time, the increased workload on the right ventricle can lead to right ventricular hypertrophy and ultimately, heart failure.
Diagnosing PH can be challenging due to its non-specific symptoms. A high index of suspicion is required, especially in patients with risk factors such as connective tissue disease, congenital heart disease, and chronic lung disease. Diagnostic tools include echocardiography, right heart catheterization, and various imaging modalities. Early diagnosis is crucial to improve patient outcomes.
Treatment of PH is multifaceted and depends on the underlying cause. Therapeutic strategies include pulmonary arterial hypertension-specific therapies, anticoagulation, oxygen therapy, and surgical options such as lung transplantation in selected cases. The goal of therapy is to improve symptoms, enhance exercise capacity, and slow disease progression.
PH is a complex disease requiring a comprehensive understanding of its pathophysiology, diagnosis, and treatment options. Early recognition and intervention can significantly improve patient outcomes. As healthcare professionals, we play a critical role in managing this challenging condition and improving the quality of life for our patients.
1.
Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.
2.
In 18 States, alcohol exclusion laws are still in effect.
3.
Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC
4.
Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer
5.
Early breast cancer detection may be possible with a wearable ultrasound scanner.
1.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
2.
A Closer Look at MCV Modules: Features, Functions, and Benefits
3.
Clonal Evolution Genomics in Dynamic Tumor Ecosystems
4.
Intratumoral Drug Distribution in Solid Tumors
5.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation